Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR)

  • Read more about RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR)
US Application 63/077,123
Filed on 2020-09-11

LZK-TARGETING DEGRADERS AND METHODS OF USE

  • Read more about LZK-TARGETING DEGRADERS AND METHODS OF USE
US Application 63/073,835
Filed on 2020-09-02

Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome

  • Read more about Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome
US Application 63/107,737
Filed on 2020-10-30

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

  • Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
US Application 63/060,340
Filed on 2020-08-03

HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION

  • Read more about HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION
US Application 63/086,674
Filed on 2020-10-02

Synthetic Self-assembling Peptide Antagonists Of Human CCR3 For The Treatment Of Inflammatory Diseases

  • Read more about Synthetic Self-assembling Peptide Antagonists Of Human CCR3 For The Treatment Of Inflammatory Diseases
US Application 62/117,486
Filed on 2015-02-18

TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS

  • Read more about TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS
US Application 63/030,815
Filed on 2020-05-27

T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATION IN P53

  • Read more about T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATION IN P53
US Application 63/074,747
Filed on 2020-09-04

HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

  • Read more about HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
US Application 63/052,502
Filed on 2020-07-16

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2

  • Read more about HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST LMP2
US Application 63/032,954
Filed on 2020-06-01

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 59
  • Page 60
  • Page 61
  • Page 62
  • Page 63
  • Page 64
  • Page 65
  • Page 66
  • Page 67
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health